We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Three-Protein Signature Blood Test Can Detect Undiagnosed Prediabetes

By LabMedica International staff writers
Posted on 11 Nov 2022
Print article
Image: Measuring levels of three proteins in the blood can aid detection of undiagnosed prediabetes (Photo courtesy of Francis Crick Institute)
Image: Measuring levels of three proteins in the blood can aid detection of undiagnosed prediabetes (Photo courtesy of Francis Crick Institute)

Medical and behavioral interventions in individuals with prediabetes are effective in delaying or preventing the onset of type 2 diabetes, but a substantial proportion of people with prediabetes are missed by current clinical screening and diagnostic techniques. Individuals with isolated impaired glucose tolerance (isolated IGT), a common subtype of prediabetes, can only be identified through oral glucose tolerance testing as they have normal results with more commonly undertaken tests. Oral glucose tolerance testing is a time-consuming procedure requiring repeated blood draws, and is not routinely performed as part of type 2 diabetes clinical screening strategies. Scientists have now used a proteomics approach to identify a three-protein signature in the blood that can improve detection of isolated IGT.

Researchers at the University of Cambridge (Cambridge, UK) used a proteomic assay to measure the levels of nearly 5,000 proteins in blood plasma samples from more than 11,000 participants in the Fenland Study, each of whom underwent an oral glucose tolerance test. The researchers created a machine learning algorithm that was able to extract a core set of few proteins out of the thousands measured that were most informative in identifying people most likely to have isolated IGT in advance of undertaking an oral glucose tolerance test.

The researchers identified a signature of only three proteins that when combined with standard screening techniques for impaired glucose tolerance improved identification of individuals with isolated IGT in the Fenland study cohort, and subsequently confirmed this finding in the independent Whitehall II study. Their results also indicate that fasting before the blood sample is taken does not significantly change the reliability of the three protein signature for identifying people with impaired glucose tolerance, which would greatly increase the application of the test in clinical practice.

The researchers suggest that by replacing the two-step screening strategy recommended by current guidelines with a three-step screening strategy that incorporates testing for the three-protein signature, the number of individuals who need to undergo oral glucose tolerance testing to identify an isolated IGT case could be substantially reduced. However, they note that some individuals with isolated IGT would still be missed, an important consideration for clinical implementation.

“The Fenland Study is unique for its size in combining genetic data and blood sampling with objective measurements of a range of clinical characteristics that includes oral glucose tolerance testing,” said PhD student Julia Carrasco Zanini. “By combining this resource with broad-capture proteomics technology we were able to identify protein signatures that substantially improved detection of impaired glucose tolerance.”

“Our strategy has the potential to address an important unmet clinical need: the identification of a meaningful proportion of people with prediabetes who currently remain undetected. Early identification would enable preventive lifestyle and behavioral interventions to improve the health of affected individuals and alleviate the burden to health-care systems caused by their delayed diagnosis,” added Professor Claudia Langenberg. “We would now like to evaluate the three-protein signature in other populations and ethnic groups, and ultimately to test the three step strategy for identifying prediabetes in randomized screening trials.”

Related Links:
University of Cambridge 

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Amoebiasis Test
ELI.H.A Amoeba
New
FOB+Transferrin+Calprotectin+Lactoferrin Test
CerTest FOB+Transferrin+Calprotectin+Lactoferrin Combo Test

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.